Cargando…
Letter to the Editor: Endocrine Compromise in Mitochondrial Disorders
Autores principales: | Finsterer, Josef, Zarrouk-Mahjoub, Sinda |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Endocrine Society
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6007250/ https://www.ncbi.nlm.nih.gov/pubmed/29942921 http://dx.doi.org/10.1210/js.2018-00093 |
Ejemplares similares
-
Costs for mitochondrial medicine will remain high as long as mitochondrial disorders are misdiagnosed()()()()
por: Finsterer, Josef, et al.
Publicado: (2017) -
MicroRNAs are inappropriate for characterising hearing impairment in mitochondrial disorders
por: Finsterer, Josef, et al.
Publicado: (2018) -
Treating mitochondrial disorders requires full exploitation of available therapeutic options
por: Finsterer, Josef, et al.
Publicado: (2017) -
Mitochondrial multiorgan disorder syndrome (MIMODS) due to a compound heterozygous mutation in the ACAD9 gene()
por: Finsterer, Josef, et al.
Publicado: (2017) -
Fibroblast growth-factor-21 is currently a weak biomarker for identifying mitochondrial and non-mitochondrial inborn errors of metabolism
por: Finsterer, Josef, et al.
Publicado: (2017)